medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-19-22-26medsovet-2742Research ArticleТАРГЕТНАЯ ТЕРАПИЯ ОПУХОЛЕЙTarget therapy of tumorsВторая линия таргетной терапии метастатического колоректального рака. Возможности выбораSecond-line targeted therapy for metastatic colorectal cancer. Possibilities for choicesБолотинаЛ. В.BolotinaL. V.

д.м.н., заведующая отделением химиотерапии

КапринА. Д.KaprinA. D.

академик РАН, д.м.н., профессор, директор

Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «НМИРЦ Минздрава России»РоссияGertsen Moscow Research Oncological Institute, Branch of National Medical Research Radiological Center of the Ministry of Health of the Russian FederationRussian Federation2018111120180192226Copyright © Болотина Л.В., Каприн А.Д., 20182018Болотина Л.В., Каприн А.Д.Bolotina L.V., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2742

Максимально эффективные режимы лекарственной терапии 1 и последующих линий метастатического колоректального рака (мКРР) предполагают включение в них таргетных препаратов (ТП). Выбор ТП для 2 линии лечения учитывает не только биологические особенности опухоли и общее состояние больного, но и вариант предшествующей линии терапии, ее эффективность и токсичность. Анти-EGFR антитела (АТ) не продемонстрировали возможности увеличения общей выживаемости (ОВ) в сравнении с ХТ в режимах 2 линии, в отличие от препаратов антиангиогенной направленности. Среди этой группы МАТ афлиберцепт обеспечивает наилучшие результаты у отобранной группы больных (группа наибольшей эффективности) и контролируемый профиль токсичности.

 

The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, aflibercept provides the best results in a selected group of patients (the highly effective group) and a controlled toxicity profile.

метастатический колоректальный рак (мКРР)таргетная терапияафлиберцептmetastatic colorectal cancer (mCRC)targeted therapyafliberceptReferencesКаприн А.Д., Старинский В.В. и др. Состояние онкологической помощи населению России в 2017 году. М., 2018.Kaprin AD, Starinsky VV, et al. The state of cancer care in Russia, 2017. M., 2018American Cancer Society. Colorectal Cancer. http://www.cancer.org/cancer/colorectal/cancer/detailedguide/colorectal-cancer-survivalrates. Accessed October 27, 2015.American Cancer Society. Colorectal Cancer. http://www.cancer.org/cancer/colorectal/cancer/detailedguide/colorectal-cancer-survivalrates. Accessed October 27, 2015.Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: Evidence in Terms of Response Rate. J. Clin. Oncol, 1992, 10: 896-903.Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: Evidence in Terms of Response Rate. J. Clin. Oncol, 1992, 10: 896-903.Vernook AP, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol., 2014, 32(5s suppl): Abstr LBA3.Vernook AP, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol., 2014, 32(5s suppl): Abstr LBA3.Schmoll HJ et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann Oncol, 2012, 23: 2479- 2516.Schmoll HJ et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann Oncol, 2012, 23: 2479- 2516.Van Cutsem Е. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27: 1386-1422. doi:10.1093/annonc/ mdw235.Van Cutsem Е. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27: 1386-1422. doi:10.1093/annonc/ mdw235.Van Cutsem Е et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 2014; 25 Suppl 3: iii1-9. doi: org/10.1093/ annonc/mdu260.Van Cutsem Е et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 2014; 25 Suppl 3: iii1-9. doi: org/10.1093/ annonc/mdu260.Sobrero AF et al. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. J Clin Oncol., 2008 May 10, 26(14): 2311-2319.Sobrero AF et al. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. J Clin Oncol., 2008 May 10, 26(14): 2311-2319.Seymour MT et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol., 2013 Jul; 14(8): 749-759.Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 2014, 25: 107-116.Seymour MT et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol., 2013 Jul; 14(8): 749-759.Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 2014, 25: 107-116.Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 2014, 25: 107-116.Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 2014, 25: 107-116.Li X et al; VEGF B a survival or an angiogenic factor? Cell Adh Migr, 2009, 3(4): 322-327.Li X et al; VEGF B a survival or an angiogenic factor? Cell Adh Migr, 2009, 3(4): 322-327.Fan Zhang et al. VEGF-B is dispensable for blood vessel growth but critical for their survival and VEGF-B targeting inhibits pathological angiogenesis. PNAS, 2009; 106: 6152-6157.Fan Zhang et al. VEGF-B is dispensable for blood vessel growth but critical for their survival and VEGF-B targeting inhibits pathological angiogenesis. PNAS, 2009; 106: 6152-6157.Arnold et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol., 2012, Li. Cell Adhesion & Migration (suppl): abstract CRA3503.Arnold et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol., 2012, Li. Cell Adhesion & Migration (suppl): abstract CRA3503.Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol, 2015, 16: 499-508 (updated 16:e262).Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol, 2015, 16: 499-508 (updated 16:e262).Van Cutsem E et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated With an OxaliplatinBased Regimen. J Clin Oncol, 2012, 30(28): 3499-3506.Van Cutsem E et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated With an OxaliplatinBased Regimen. J Clin Oncol, 2012, 30(28): 3499-3506.Mitchell et al. Evaluation of the Effect of Aflibercept on OS by Timing of First-Line Disease Progression: A Post-Hoc Analysis of the VELOUR Trial. Ann Oncol, 2014, 25(suppl2): abstract P-0226.Mitchell et al. Evaluation of the Effect of Aflibercept on OS by Timing of First-Line Disease Progression: A Post-Hoc Analysis of the VELOUR Trial. Ann Oncol, 2014, 25(suppl2): abstract P-0226.Van Cutsem E et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol, 2016, 11: 383-400; epub. doi: 10.1007/s11523-015-0402-9.Van Cutsem E et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol, 2016, 11: 383-400; epub. doi: 10.1007/s11523-015-0402-9.Chau et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer., 2014; 14: 605.Chau et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer., 2014; 14: 605.Martin AJM, Casado AR, Millan PI et al. Colorectal metastases resection after FOLFIRIAflibercept (FA) in oxaliplatin-refractory patients. ASCO GI, 2018. 20. Tessen HW et al. The colorectal carcinoma – treatment research and treatment reality in oncology practices (Anti-VEGF or Anti-EGFR therapies). Annals of Oncology, 2016, 27(6): 498. doi: org/10.1093/annonc/mdw370.46.Martin AJM, Casado AR, Millan PI et al. Colorectal metastases resection after FOLFIRIAflibercept (FA) in oxaliplatin-refractory patients. ASCO GI, 2018. 20. Tessen HW et al. The colorectal carcinoma – treatment research and treatment reality in oncology practices (Anti-VEGF or Anti-EGFR therapies). Annals of Oncology, 2016, 27(6): 498. doi: org/10.1093/annonc/mdw370.46.

The authors declare that there are no conflicts of interest present.